Search

Displaying results 2561 - 2570 of 10000 in total
  1. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [A274581] On December 19, 2025, the U.S. FDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults.

  2. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    [A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098] … Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain

  3. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    in 2-hydroxyglutarate (2-HG), a metabolite that participates in tumerogenesis. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.

  4. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. … [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017.

    Synonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
  5. Drug

    Dimethicone 410

    go.drugbank.com/drugs/DB14005
    Approved

    [L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%. … Dimethicone is a silicone-based polymer used as a moisturizer in different skin OTC products.[A32462] It is formed by repeated polymeric units of -(CH3)2SiO- with a terminal trimethyl siloxy unit.

  6. Drug

    Desflurane

    go.drugbank.com/drugs/DB01189
    ApprovedInvestigational

    It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]

  7. Drug

    Bismuth subgallate

    go.drugbank.com/drugs/DB13909
    Approved

    Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet elucidated antimicrobial and hemostatic actions, bismuth subgallate is most commonly available as an over-the-counter … Bismuth subgallate is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight.

  8. Drug

    Bismuth subnitrate

    go.drugbank.com/drugs/DB13209
    ApprovedWithdrawn

    The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.

  9. Drug

    Tyloxapol

    go.drugbank.com/drugs/DB06439
    ApprovedInvestigational

    Tyloxapol is a non-ionic detergent often used as a surfactant.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. … [A244920] Palovarotene was approved for use in Canada in January 2022 for the management of heterotopic ossification (HO) in patients with FOP, representing the first global approval for any FOP therapy